TFS HealthScience has received validation from the Science Based Targets initiative (SBTi) for its near-term and net-zero greenhouse gas reduction goals, underscoring its commitment to science-based decarbonization and a healthier, more sustainable world.
TFS HealthScience, a leading global Contract Research Organization, is expanding its ophthalmology business unit with new leadership talent and enhanced delivery capabilities to meet rising demand for specialized clinical trial execution in eye care.
Markus Granlund, who has been serving as Interim CEO of TFS HealthScience since February 2025, has officially been appointed as the company’s Chief Executive Officer, effective immediately.
TFS HealthScience has been named a 2025 Life Sciences Award winner by Triangle Business Journal in recognition of its scientific expertise, operational excellence, and growing impact within North Carolina’s dynamic life sciences ecosystem.
LUND, S.E., April 2, 2025 – TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), announces continued advancement in its sustainability journey, marked by a strengthened assessment from CDP, formerly the Carbon Disclosure Project.
LUND, S.E., March 25, 2025 – TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is pleased to announce that Miriam Martin, a long-standing member of the organization, has…
TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is pleased to announce the appointment of Katarina Ageborg as Chairman of the Board and Markus Granlund as acting CEO, effective immediately.
TFS HealthScience proudly announces the launch of its new mission statement and tagline: Empowering Partners. Enriching Lives. This strategic shift underscores TFS’s commitment to advancing clinical research, improving patient outcomes, and fostering sustainable partnerships.
TFS HealthScience partners with RetinAI and MAXO to advance clinical studies in dry eye disease with AI-driven data management and innovative solutions.
TFS appoints Kris O’Brien as VP, Head of Oncology & Rare Diseases, enhancing leadership in clinical trials for complex therapies.
